Generic Name: Omalizumab (Drug Plan Submission)
Brand Name: Xolair
Manufacturer: Novartis Pharmaceuticals Canada Inc.
Indications: Asthma, severe persistent
Submission Type: Drug Plan Initiated
Project Status: Complete
Date Recommendation Issued: May 18, 2016
Recommendation Type: Reimburse with clinical criteria and/or conditions